This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
WIERDA, WILLIAM G
| Item Type | Name |
|
Concept
|
Receptors, Antigen
|
|
Concept
|
Receptors, Antigen, T-Cell
|
|
Concept
|
Receptors, Antigen, B-Cell
|
|
Academic Article
|
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
|
|
Academic Article
|
CARs in chronic lymphocytic leukemia -- ready to drive.
|
|
Academic Article
|
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
|
|
Academic Article
|
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Ibrutinib: a paradigm shift in management of CLL.
|
|
Academic Article
|
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.
|
|
Academic Article
|
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
|
|
Academic Article
|
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
|
|
Academic Article
|
Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations
|
|
Academic Article
|
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
|
|
Academic Article
|
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
|
|
Academic Article
|
Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
|
|
Academic Article
|
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
|
|
Academic Article
|
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
|
|
Academic Article
|
Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy.
|
|
Academic Article
|
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
|
|
Academic Article
|
Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should?Know.
|
|
Academic Article
|
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
|
|
Academic Article
|
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.
|
|
Academic Article
|
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
|
|
Academic Article
|
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase.
|
|
Academic Article
|
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
|